In Vivo Base Editing of PCSK9 with Verve-102 for Hypercholesterolemia
A phase 1b clinical trial tested Verve-102, a base-editing therapy targeting PCSK9, in patients with hypercholesterolemia. The treatment reduced LDL cholesterol levels, though some patients experienced infusion reactions. The study provides early evidence for in vivo base editing as a potential one-time treatment for high cholesterol.